4,899 results match your criteria Factor XIII


Premarital Screening Program for Congenital Factor XIII Deficiency in Iran.

Clin Lab 2020 Aug;66(8)

Background: Factor XIII deficiency is one of the most severe congenital bleeding disorders with high rate of life-threatening bleeding including central nervous system bleeding, umbilical cord bleeding, and recurrent miscarriages. Due to the highest global incidence of the disorder in Iran, this study aimed to design a premarital screening program in Iran.

Methods: This descriptive study was performed on 30 couples with a positive family history of factor XIII deficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2020.191133DOI Listing

[Acquired autoimmune coagulation factor XIII/13 deficiency].

Authors:
Yoshiyuki Ogawa

Rinsho Ketsueki 2020 ;61(7):799-808

Department of Hematology, Gunma University Hospital.

Coagulation factor XIII/13 (FXIII) is a transglutaminase that cross-links fibrin monomers, provides clot stabilization and resistance to fibrinolysis and proteolysis, and ultimately contributes to hemostasis and wound healing. FXIII is a hetero-tetramer formed by two catalytic A subunits (FXIII-A) and two noncatalytic B subunits (FXIII-B). Autoimmune acquired factor XIII/13 deficiency secondary to anti-FXIII antibodies (AH13) is a severe bleeding disorder that occurs mainly in the elderly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.799DOI Listing
January 2020

[Acquired coagulation disorders].

Authors:
Nobuaki Suzuki

Rinsho Ketsueki 2020 ;61(7):779-784

Department of Transfusion Medicine, Nagoya University Hospital.

Acquired coagulation inhibitors have become a popular area of research because they cause severe bleeding tendency in many patients. The use of acquired coagulation inhibitors requires rapid and precise diagnosis. Some acquired coagulation inhibitors show prolongation in the activated partial thromboplastin time (APTT) and/or prothrombin time (PT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.779DOI Listing
January 2020

The Need for Red Cell Support During Non-Cardiac Surgery Is Associated to Pre-Transfusion Levels of FXIII and the Platelet Count.

J Clin Med 2020 Jul 31;9(8). Epub 2020 Jul 31.

University of Bern, Hochschulstrasse 6, 3012 Bern, Switzerland.

Unexpected intraoperative bleeding is associated with a reduced availability of crosslinking capacity (provided through factor XIII (FXIII)) per unit of generated thrombin. Furthermore, FXIII deficiency and thrombocytopenia (but not fibrinogen deficiency) are the most prevalent modulators of clot firmness in the immediate postoperative setting. In this study, we therefore evaluated whether levels of FXIII, fibrinogen, or the platelet count influenced the probability of intraoperative red cell transfusions in patients in the operating theatre. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9082456DOI Listing

Effectiveness of Factor XIII Infusion in Treatment of Refractory Ureteral Leakage after Kidney Transplantation.

Case Rep Transplant 2020 16;2020:1780760. Epub 2020 Jul 16.

Department of Urology, Osaka Medical College, Osaka, Japan.

Despite the evolution of transplantation techniques, urological complications are common and result in loss of graft. We report the case of a 57-year-old man who developed continuous urine leakage despite pyeloureteral neoanastomosis and stenting after kidney transplantation from his dizygotic twin. Suspecting ureteral leakage, we performed pyeloureteral neoanastomosis using his native right ureter and a ureteral stent 5 days after the kidney transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/1780760DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381963PMC

A case of life-threatening small intestinal bleeding accompanied by lower coagulation factor XIII activity.

Clin J Gastroenterol 2020 Jul 24. Epub 2020 Jul 24.

Department of Medicine, Seta Tsukinowa, Shiga University of Medical Science, Otsu, 520-2192, Japan.

We report a case of life-threatening bleeding from the small intestine accompanied by lower coagulation factor XIII (FXIII) activity. A 43-year-old man was admitted because of continuous small intestinal bleeding. He had no family or past history of bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-020-01195-4DOI Listing

Sustained Depletion of FXIII-A by Inducing Acquired FXIII-B Deficiency.

Blood 2020 Jul 17. Epub 2020 Jul 17.

Michael Smith Laboratories, Canada.

The activated form of coagulation factor XIII (FXIII-A2B2), FXIII-A*, is a hemostatic enzyme essential for inhibiting fibrinolysis, by irreversibly crosslinking fibrin and antifibrinolytic proteins. Despite its importance, there are no modulatory therapeutics. Guided by the observation that humans deficient in FXIII-B have reduced FXIII-A without severe bleeding, we hypothesized that a suitable small interfering RNA (siRNA) targeting hepatic FXIII-B could safely decrease FXIII-A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020004976DOI Listing

Novel fibrin-fibronectin matrix accelerates mice skin wound healing.

Bioact Mater 2020 Dec 1;5(4):949-962. Epub 2020 Jul 1.

Nursing School, University of Campinas, Campinas, SP, Brazil.

Plasma fibrinogen (F1) and fibronectin (pFN) polymerize to form a fibrin clot that is both a hemostatic and provisional matrix for wound healing. About 90% of plasma F1 has a homodimeric pair of γ chains (γγF1), and 10% has a heterodimeric pair of γ and more acidic γ' chains (γγ'F1). We have synthesized a novel fibrin matrix exclusively from a 1:1 (molar ratio) complex of γγ'F1 and pFN in the presence of highly active thrombin and recombinant Factor XIII (rFXIIIa). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioactmat.2020.06.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334397PMC
December 2020

Survival time and prognostic factors after whole-brain radiotherapy of brain metastases from of breast cancer.

Acta Radiol Open 2020 Jul 6;9(7):2058460120938744. Epub 2020 Jul 6.

Department of Surgery, Division of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Japan.

Background: Breast cancer has a poor prognosis due to the high risk of distant metastasis.

Purpose: To identify the prognosticators of brain metastasis from breast cancer treated by whole-brain radiotherapy.

Material And Methods: We evaluated patients diagnosed with primary brain metastasis without carcinomatous meningitis from breast cancer and had undergone whole-brain radiotherapy as initial treatment between 1 January 2010 and 30 September 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2058460120938744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338738PMC

How Much Is the Inevitable Loss of Different Coagulation Factors During Blood Product-Free Liver Transplantations?

Transplant Proc 2020 Jul 8. Epub 2020 Jul 8.

Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary.

Background: Bloodless liver transplantations (LT) have already been reported, but special characteristics of hemostatic changes remain less defined. The aim of this study was to evaluate the "inevitable" loss of coagulation factors (CF) in blood product-free LT.

Methods: Blood product and CF concentrate-free LT patient data were analyzed in terms of the first 2 days of perioperative hemostasis kinetics (N = 59). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2020.05.006DOI Listing

Factor XIII Deficiency with a Novel Nonsense Mutation.

Indian J Hematol Blood Transfus 2020 Jul 22;36(3):588-589. Epub 2020 Feb 22.

MedGenome Labs Ltd, Bangalore, 560099 India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-020-01262-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326742PMC
July 2020
0.234 Impact Factor

The effects of genetic polymorphisms and diabetes mellitus on the development of peripheral artery disease.

Turk Kardiyol Dern Ars 2020 Jul;48(5):484-493

Department of Cardiology, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.

Objective: Peripheral artery disease (PAD) is a condition caused by the narrowing of limb arteries due to atherosclerosis. In recent years, polymorphisms in a number of genes have been shown to contribute to the risk of PAD development. However, whether the contribution of these inheritable factors is independent of traditional cardiovascular risk factors remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5543/tkda.2020.15686DOI Listing

A Novel Assay for Detection of Methicillin-Resistant Directly From Clinical Samples.

Front Microbiol 2020 18;11:1295. Epub 2020 Jun 18.

Centre for Antimicrobial Resistance, Alberta Health Services/Alberta Precision Laboratories/University of Calgary, Calgary, AB, Canada.

The timely detection of Methicillin-resistant (MRSA) is crucial for antimicrobial therapy and a key factor to limit the hospital spread of MRSA. Currently available commercial MRSA detection assays target the 3' end of the gene and the right extremity of Staphylococcal Cassette Chromosome (SCC). These assays suffer from both false positive due to SCC-like elements that lack and false negative results due to the inability to detect new or variant SCC cassettes with the existing primers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmicb.2020.01295DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314949PMC

Acute kidney injury in decompensated cirrhosis is associated with both hypo- and hyper-coagulable features.

Hepatology 2020 Jul 2. Epub 2020 Jul 2.

Digestive Disease Section, Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Background & Aim: Recent evidence suggests that acute kidney injury (AKI) is the main predictor of post-paracentesis bleeding in patients with cirrhosis. To assess factors responsible for bleeding tendency in AKI, we performed a prospective study comparing all three aspects of hemostasis (platelets, coagulation, fibrinolysis) in patients with decompensated cirrhosis with and without AKI.

Approach & Results: Primary hemostasis assessment included platelet aggregation and secretion (platelet function markers) and von Willebrand factor (VWF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.31443DOI Listing

Genetic Variants in the and Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.

Int J Mol Sci 2020 Jun 29;21(13). Epub 2020 Jun 29.

National Center of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, 03601 Martin, Slovakia.

Fibrinogen is a hexameric plasmatic glycoprotein composed of pairs of three chains (Aα, Bβ, and γ), which play an essential role in hemostasis. Conversion of fibrinogen to insoluble polymer fibrin gives structural stability, strength, and adhesive surfaces for growing blood clots. Equally important, the exposure of its non-substrate thrombin-binding sites after fibrin clot formation promotes antithrombotic properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21134616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369898PMC

Short-term Outcomes of Arthroscopic Partial Repair vs Latissimus Dorsi Tendon Transfer in Patients with Massive and Partially Repairable Rotator Cuff Tears.

J Shoulder Elbow Surg 2020 Jun 27. Epub 2020 Jun 27.

Institut Locomoteur de l'Ouest, 7 Bouclevard de la Boutière, 35760 Saint - Grégoire, FRANCE.

Background: There is limited evidence on clinical outcomes of APR and LDTT for posterosuperior mRCTs. We aimed to compare clinical outcomes of APR and LDTT for partially repairable posterosuperior mRCTs, and determine whether outcomes differ among tears that involve the teres minor.

Methods: We retrieved records of 112 consecutive patients with mRCTs deemed partially repairable due to fatty infiltration (FI) stage ≥3 in one or more rotator cuff muscles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jse.2020.06.002DOI Listing

Effect of early cryoprecipitate transfusion versus standard care in women who develop severe postpartum haemorrhage (ACROBAT) in the UK: a protocol for a pilot cluster randomised trial.

BMJ Open 2020 Jun 21;10(6):e036416. Epub 2020 Jun 21.

Barts Research Centre for Women's Health (BARC), Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Introduction: The incidence of severe postpartum haemorrhage (PPH) that requires blood transfusion is on the increase. Fibrinogen levels have been shown to drop early and significantly during PPH, which is associated with worse outcomes. Early fibrinogen replacement could potentially improve outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2019-036416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311066PMC
June 2020
2.063 Impact Factor

The Structure of Blood Coagulation Factor XIII Is Adapted to Oxidation.

Biomolecules 2020 Jun 17;10(6). Epub 2020 Jun 17.

N. M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.

The blood coagulation factor XIII (FXIII) plays a critical role in supporting coagulation and fibrinolysis due to both the covalent crosslinking of fibrin polymers, rendering them resistant to plasmin lysis, and the crosslinking of fibrin to proteins of the fibrinolytic system. The hypochlorite-mediated oxidation of the blood coagulation factor XIII (FXIII) at the different stages of its enzymatic activation is studied for the first time in this paper. The consolidated results obtained with the aid of MS/MS, electrophoresis, and colorimetry demonstrate that in the process of FXIII's conversion into FXIIIa, the vulnerability of FXIII to hypochlorite-induced oxidation increased as follows: native FXIII < FXIII + Ca < FXIII + Ca/thrombin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biom10060914DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355775PMC

A neonate bearing a novel genetic variant within the factor XIII active site presenting with severe umbilical haemorrhage.

Haemophilia 2020 Jun 18. Epub 2020 Jun 18.

Division of Pediatric Hematology/Oncology, Children's Hospital at Montefiore, Bronx, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.14074DOI Listing

Coagulation factor XIII activity predicts left ventricular remodelling after acute myocardial infarction.

ESC Heart Fail 2020 Jun 17. Epub 2020 Jun 17.

Comprehensive Heart Failure Center Würzburg, University Hospital Würzburg, Würzburg, Germany.

Aims: Acute myocardial infarction (MI) is the major cause of chronic heart failure. The activity of blood coagulation factor XIII (FXIIIa) plays an important role in rodents as a healing factor after MI, whereas its role in healing and remodelling processes in humans remains unclear. We prospectively evaluated the relevance of FXIIIa after acute MI as a potential early prognostic marker for adequate healing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ehf2.12774DOI Listing

Analysis of thrombophilic gene mutations in coronary artery ectasia.

Turk Kardiyol Dern Ars 2020 Jun;48(4):368-373

Departments of Cardiology, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.

Objective: Coronary artery ectasia (CAE) is defined as localized or diffuse dilatation in the coronary artery lumen of at least 1.5 times the diameter of adjacent healthy reference segments. The etiology of CAE is still unknown, but the most likely cause is atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5543/tkda.2019.99789DOI Listing

Acquired FXIII inhibitor: Patient characteristics and treatment outcome, a case series in Taiwan.

J Formos Med Assoc 2020 Jun 5. Epub 2020 Jun 5.

Department of Internal Medicine, Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan; Division of Hematology and Oncology, Changhua Christian Hospital, Changhua County, Taiwan. Electronic address:

Introduction: Acquired factor XIII (FXIII) inhibitor is a rare but possibly underdiagnosed bleeding disorder. To date, less than one hundred cases have been reported, but the number has increased rapidly in recent years, especially in Japan. Because of the rarity of this disorder, no treatment guidelines are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfma.2020.05.032DOI Listing

Feasibility of an automated coagulation factor XIIIa test using its isopeptidase activity.

Anal Biochem 2020 07 15;600:113757. Epub 2020 May 15.

Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Brunner Str. 67, 1230, Vienna, Austria. Electronic address:

Plasma transglutaminase FXIII provides mechanical and biochemical stability to blood clots. Congenital or acquired deficiency may be associated with bleeding diathesis and requires therefore careful monitoring. The precise automated measurement of a large number of plasma samples can provide new insights regarding the clinical relevance of certain FXIII levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2020.113757DOI Listing

Refractory non-variceal upper gastrointestinal bleeding in a liver-transplant patient: Everolimus withdrawal should be considered.

Therapie 2020 May 8. Epub 2020 May 8.

Service de médecine intensive réanimation & Inserm U1121 & FMTS, faculté de médecine de strasbourg, avenue Molière, hôpitaux universitaires de Strasbourg, 67098 Strasbourg, France; Centre régional de pharmacovigilance, hôpitaux universitaires de Strasbourg, 67091, Strasbourg, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.therap.2020.04.006DOI Listing

Fibrinogen, factor XIII and α-antiplasmin genotypes are associated with inflammatory activity and anti-citrullinated protein antibodies.

Thromb Res 2020 07 3;191:90-96. Epub 2020 May 3.

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charité-Platz 1, 10117 Berlin, Germany.

Background: Fibrin(ogen) derivatives, crosslinked fibrin and fibrinolysis play important roles in inflammation and are involved in pathogenesis of rheumatoid arthritis (RA). About 2/3 of RA patients exhibit anti-citrullinated protein antibodies (ACPA) that target deiminated fibrinogen. Genetic variants of β-fibrinogen (FGB) (rs1800790G>A) and factor XIII A-subunit (F13A) Val34Leu (rs5985) are known to influence interactively inflammatory processes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2020.04.043DOI Listing

Experimental analysis of T cell epitopes for designing liver cancer vaccine predicted by system-level immunoinformatics approach.

Am J Physiol Gastrointest Liver Physiol 2020 Jun 4;318(6):G1055-G1069. Epub 2020 May 4.

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.

Liver cancer is a worldwide disease, and, currently, due to the poor prognostic and therapeutic options of liver cancer, we investigated the T cell epitopes as potential therapeutic vaccine candidates to get the benefit of experimental processes and utilize the complete ability of the immune system compared with other artificial ex vivo proliferation of T cells. Activation of T cells targets and kills several tumors, developing a strong rationale for the improvement of immunotherapeutic strategies to cancer therapy. To predict T cell epitopes for liver cancer, we designed a comprehensive immunoinformatics framework involving data mining, immunogenicity prediction, functional proteomic analysis, conservation studies, molecular modeling, and in vivo validation analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpgi.00068.2020DOI Listing
June 2020
3.798 Impact Factor

Gynecological and obstetric outcome in the French cohort of women with factor XIII deficiency.

Thromb Res 2020 07 21;191:22-25. Epub 2020 Apr 21.

Hospices Civils de Lyon, Unité Hémostase Clinique, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.

Introduction: Congenital factor XIII deficiency is a very rare bleeding disorder affecting 33 patients in France. Besides its role in fibrin clot stabilization, factor XIII is involved in placental attachment. Fetal miscarriages represent a frequent and concerning issue for these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2020.04.010DOI Listing

Inhibitors of blood coagulation factor XIII.

Anal Biochem 2020 Apr 23:113708. Epub 2020 Apr 23.

Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address:

The blood coagulation factor XIII (FXIII) plays an essential role in the stabilization of fibrin clots. This factor, belonging to the class of transglutaminases, catalyzes the final step of secondary hemostasis, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2020.113708DOI Listing

Protein-peptide based assay for the characterization of human blood coagulation factor XIII-A isopeptidase activity.

Anal Biochem 2020 07 23;600:113699. Epub 2020 Apr 23.

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary. Electronic address:

Blood coagulation factor XIII-A (FXIII-A), a member of the transglutaminase enzyme family, is best known for its fibrin clot stabilizing function during blood coagulation. It possesses amine incorporating and protein crosslinking transamidase activities, but it is also able to cleave the previously formed isopeptide bond by its isopeptidase activity. Our aim was to develop a protein-based assay for better characterization of FXIII-A isopeptidase activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2020.113699DOI Listing

In-vitro assessment of the effects of fibrinogen, recombinant factor VIIa and factor XIII on trauma-induced coagulopathy.

Blood Coagul Fibrinolysis 2020 Jun;31(4):253-257

Faculty of Engineering, Holon Institute of Technology, Holon, Israel.

: Trauma-induced coagulopathy (TIC) occurs commonly as a second event following severe injury. We evaluated the effects of fibrinogen, recombinant factor VIIa and factor XIII on blood clotting and fibrinolysis in an in-vitro TIC model. The TIC model included hemodilution, hyperfibrinolysis, acidosis and hypothermia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MBC.0000000000000910DOI Listing

Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype.

J Thromb Haemost 2020 Jun 27;18(6):1330-1334. Epub 2020 Apr 27.

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Hemorrhagic diathesis due to anti-factor XIII (FXIII) autoantibody is a rare but severe disorder. Challenges of the diagnosis and treatment is demonstrated by the case of a 67-year-old female without previous bleeding history, who suffered a huge muscular hematoma. Without blank subtraction 18% plasma FXIII activity was measured; however, after correction for blank the activity was below the limit of detection and the lack of fibrin cross-linking in the patient's plasma confirmed the latter result. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14811DOI Listing

Hemophilia C: A Case Report With Updates on Diagnosis and Management of a Rare Bleeding Disorder.

J Hematol 2019 Sep 30;8(3):144-147. Epub 2019 Sep 30.

Division of Hematology Oncology, Department of Medicine, Allegheny General Hospital, Pittsburgh, PA 15212, USA.

Hemophilia C or factor XI deficiency is a rare clotting disorder with prevalence of only 1 per 1 million. A 24-year-old male with multiple abdominal surgeries complicated by wound infections and poor healing was admitted to plastic surgery service for an elective abdominoplasty. Hematology was consulted for increased intraoperative and postoperative bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/jh522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153668PMC
September 2019

Factor XIII as a potential predictor of severe gastrointestinal involvement in Henoch Schoenlein purpura: A case study research.

J Paediatr Child Health 2020 Apr 15. Epub 2020 Apr 15.

Pediatric Rheumatology Unit, SS Annunziata Hospital, Chieti, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jpc.14886DOI Listing

Advances in managing rare acquired bleeding disorders.

Expert Rev Hematol 2020 Jun 23;13(6):599-606. Epub 2020 Apr 23.

Italian National Blood Centre, National Institute of Health , Rome, Italy.

Introduction: Rare acquired bleeding disorders include a wide spectrum of coagulopathies characterized by spontaneous or post-trauma and post-surgery hemorrhages in patients without a previous personal or family history of bleeding.

Areas Covered: This review, based on a Medline/PubMed search during the last 20 years, will focus mainly on rare acquired bleeding disorders caused by autoantibodies against coagulation factors, including autoantibodies against factor VIII (acquired hemophilia A), von Willebrand factor (acquired von Willebrand syndrome) and other coagulation factors (factors V, X, XI, and XIII). The pathogenic, laboratory, and clinical features of these rare hemorrhagic conditions will be discussed, with particular attention to their management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2020.1756259DOI Listing

Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients.

Vasc Health Risk Manag 2020 1;16:103-110. Epub 2020 Apr 1.

First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.

Background: The aim was to evaluate factor XIII activity (FXIIIa) and monocyte-derived microparticles (MDMPs) in cancer patients.

Methods: In total, 138 cancer patients (31 malignant lymphomas, 39 multiple myelomas, and 68 lung cancers) were analyzed. We measured various biomarkers including FXIIIa and MDMPs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/VHRM.S240500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131992PMC

Tumor-Draining Lymph Secretome En Route to the Regional Lymph Node in Breast Cancer Metastasis.

Breast Cancer (Dove Med Press) 2020 25;12:57-67. Epub 2020 Mar 25.

Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.

Background: During metastasis, tumor cells metastasize from primary tumors to distant organs via the circulatory and the lymphatic systems. There is a plethora of information about metastasis through the circulatory system, however not much information is available about the tumor cells dissemination through the lymphatic system or the lymphatic microenvironment that aids in this process in breast cancer metastasis.

Purpose: The study designed to examine the tumor-derived secretome in lymph before reaching the draining lymph nodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BCTT.S236168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104086PMC

Proteomic Analysis of Renal Biomarkers of Kidney Allograft Fibrosis-A Study in Renal Transplant Patients.

Int J Mol Sci 2020 Mar 30;21(7). Epub 2020 Mar 30.

Department of Clinical Biochemistry and Pharmacology, Centre for Clinical Proteomics, Odense University Hospital, DK-5000 Odense, Denmark.

Renal transplantation is the preferred treatment of end stage renal disease, but allograft survival is limited by the development of interstitial fibrosis and tubular atrophy in response to various stimuli. Much effort has been put into identifying new protein markers of fibrosis to support the diagnosis. In the present work, we performed an in-depth quantitative proteomics analysis of allograft biopsies from 31 prevalent renal transplant patients and correlated the quantified proteins with the volume fraction of fibrosis as determined by a morphometric method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21072371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177439PMC

Structure-Based Design of FXIIIa-Blockers: Addressing a Transient Hydrophobic Pocket in the Active Site of FXIIIa.

ChemMedChem 2020 May 7;15(10):900-905. Epub 2020 Apr 7.

Department of Pharmaceutical Chemistry, Philipps-Universität, Marbacher Weg 6, 35032, Marburg, Germany.

Blood coagulation factor XIII (FXIII, F13) is considered to be a promising target for anticoagulants with reduced bleeding risk because of its unique position in the coagulation cascade downstream of thrombin. However, until now, no potent drug addressing FXIII has been available, indeed no compound has even entered clinical trials yet. In 2013, we published the co-crystal structure of FXIII in the active state (FXIIIa°), thereby providing a detailed map of the active site for the rational design of potent FXIIIa blockers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.202000056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317430PMC

The impact of prepartum factor XIII activity on postpartum blood loss.

J Thromb Haemost 2020 Jun 16;18(6):1310-1319. Epub 2020 Apr 16.

Department of Obstetrics, University Hospital Zurich, Zurich, Switzerland.

Background: Postpartum hemorrhage (PPH), a major cause of maternal mortality, has several known risk factors but frequently occurs unexpectedly. PPH incidence and related maternal morbidity and mortality are rising worldwide.

Objective: To evaluate the impact of defined prepartum blood coagulation parameters on postpartum blood loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14795DOI Listing

N-glycosylation of blood coagulation factor XIII subunit B and its functional consequence.

J Thromb Haemost 2020 Jun 15;18(6):1302-1309. Epub 2020 Apr 15.

Horváth Csaba Memorial Laboratory of Bioseparation Sciences, Research Center for Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Background: The protective/inhibitory B subunits of coagulation factor XIII (FXIII-B) is a ~80 kDa glycoprotein containing two N-glycosylation sites. Neither the structure nor the functional role of the glycans on FXIII-B has been explored.

Objective: To reveal the glycan structures linked to FXIII-B, to design a method for deglycosylating the native protein, to find out if deglycosylation influences the dimeric structure of FXIII-B and its clearance from the circulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14792DOI Listing

Complete hemostasis achieved by factor XIII concentrate administration in a patient with bleeding after teeth extraction as a complication of aplastic anemia and chronic disseminated intravascular coagulation.

Blood Coagul Fibrinolysis 2020 Jun;31(4):274-278

Department of Hematology, Kanazawa University Hospital, Ishikawa.

: Hemostatic treatment of disseminated intravascular coagulation (DIC) due to aortic aneurysm involves numerous difficulties. An 89-year-old man with aplastic anemia and chronic DIC developed periodontitis and loose teeth requiring extraction, after which hemostasis was difficult. Platelet concentrates and fresh-frozen plasma transfusions were ineffective, and there was a risk of hemorrhage; therefore, administration of anticoagulant agents for DIC was inappropriate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MBC.0000000000000902DOI Listing

Ex vivo effect of hemostatic therapy in subarachnoid and intracerebral hemorrhage.

Thromb Res 2020 05 26;189:42-47. Epub 2020 Feb 26.

Thrombosis and Hemostasis Research Unit, Department of Clinical Biochemistry; Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University; Aarhus, Denmark. Electronic address:

Background: Rebleeding and hematoma growth are serious complications in subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH). As treatment options are sparse, a mechanistic approach may reveal new therapeutic targets.

Aim: Firstly, to evaluate hemostasis using a sensitive low tissue factor thromboelastometry (ROTEM®) assay in patients with SAH or ICH and compare them with healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2020.02.012DOI Listing

Acquired Factor XIII Deficiency Inducing Recurrent and Fatal Bleeding, Description of a Case.

J Blood Med 2020 30;11:43-45. Epub 2020 Jan 30.

Department of Internal Medicine and Emergency Room, Fatebenefratelli Hospital of Naples, Naples, Italy.

Factor XIII deficiency may be inherited or acquired. Inherited deficiency is associated with signs and symptoms of minor bleeding from a young age, and possible major bleeding complications, in particular during pregnancy. On the other hand, acquired factor XIII deficiency is usually associated with severe symptoms of major bleeding, in particular during surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JBM.S232115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996541PMC
January 2020

Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.

J Thromb Thrombolysis 2020 Feb 15. Epub 2020 Feb 15.

Unidad de Hemostasia Y Trombosis, Servicio de Hematología, Hospital Universitario Y Politécnico La Fe, Valencia, Spain.

Coagulation factor XIII (FXIII) has a major role in coagulation stabilizing the haemostatic clot. FXIII deficiency is associated with an increased risk of bleeding. Severe phenotypes lead to spontaneous, traumatic and surgical bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-020-02065-zDOI Listing
February 2020

Impact of Intraoperative Cell Salvage on Blood Coagulation Factor Concentrations in Patients Undergoing Cardiac Surgery.

Anesth Analg 2020 05;130(5):1389-1395

From the Departments of Anaesthesiology, Intensive Care Medicine and Pain Therapy.

Background: Cardiothoracic surgery is associated with major blood loss and allogeneic transfusion of red blood cell concentrates. To minimize allogeneic red blood cell (RBC) transfusion, intraoperative cell salvage has been effectively used for years. The objective of this study was to evaluate the impact of cell salvage on blood coagulation factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1213/ANE.0000000000004693DOI Listing

Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome.

Acta Obstet Gynecol Scand 2020 Aug 3;99(8):1078-1084. Epub 2020 Mar 3.

Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.

Introduction: Polycystic ovary syndrome (PCOS) is characterized by increased central fat mass (CFM), hyper-inflammation, and hemostatic alterations; the risk of cardiovascular disease may also be increased. Reduced fibrin lysability is a risk factor for cardiovascular disease. The present study assessed fibrin lysability in women with PCOS and controls of similar age and body mass index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13825DOI Listing

Dynamics of coagulation factor XIII activity after video-assisted thoracoscopic lobectomy for non-small cell lung cancer.

J Thorac Dis 2019 Dec;11(12):5382-5389

Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.

Background: The present study was performed to investigate the perioperative dynamics of coagulation factor XIII (FXIII) in patients with non-small cell lung cancer undergoing video-assisted thoracoscopic surgery (VATS) lobectomy compared with open lobectomy.

Methods: Perioperative coagulation factors including FXIII were analyzed in 30 patients who underwent VATS lobectomy and 10 patients who underwent open lobectomy at Teikyo University Hospital from December 2017 to April 2019.

Results: Patients in the VATS lobectomy group showed higher FXIII activity on postoperative day (POD) 5 than patients in the open lobectomy group (P=0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.12.08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988064PMC
December 2019